Furthermore, BET inhibitors can downregulate PD-L1 expression on solid tumor cells (76, 77), thus facilitating the activation of immune checkpoints and long-term LSC clearance, in a similar manner to the suppression of PD1 on T cells in CML patients with TKI-induced deep molecular response (66). This evidence concerns the gene DNER and chronic myelogenous leukemia, BCR-ABL1 positive.